Introduction: Why a Single Nitrosamine Testing Panel Is Insufficient for Cardiac Drug Classes
Understanding drug-class-specific nitrosamine chemistry is one of the most critical aspects of developing an effective impurity control strategy. Nitrosamine testing for beta-blockers, ACE inhibitors, and sartans cannot be conducted using a universal testing panel because each therapeutic class possesses a distinct chemical environment, different impurity precursors, and unique structural factors that influence N-nitrosamine formation. Applying a sartan-focused NDMA/NDEA analytical method to a beta-blocker drug product, for example, may fail to identify structurally unique nitrosamine drug substance-related impurities (NDSRIs) that regulatory agencies specifically require manufacturers to assess and characterize for that drug class.
Since the discovery of N-nitrosodimethylamine (NDMA) in valsartan API in 2018, which was linked to tetrazole ring synthesis processes at Zhejiang Huahai Pharmaceutical, regulatory expectations have evolved significantly. Authorities including the FDA, EMA, Health Canada, and TGA have established a layered compliance framework that recognizes the unique nitrosamine risks associated with different drug classes. The FDA’s Revision 2 guidance issued in September 2024 formally distinguished small-molecule nitrosamines from nitrosamine drug substance-related impurities (NDSRIs), reinforcing the expectation that both manufacturers and contract research organizations (CROs) possess specialized, drug-class-specific expertise.
The Chemistry of Nitrosamine Formation Varies Across These Three Drug Classes
The nitrosamine impurity profile of a cardiovascular drug product is influenced by several factors, including synthetic route design, functional group chemistry, excipient selection, and storage conditions. These factors differ substantially among sartans, ACE inhibitors, and beta-blockers, resulting in unique nitrosamine formation pathways.
Sartans: Tetrazole-Driven Small-Molecule Nitrosamine Formation
Sartans containing a tetrazole ring, including candesartan, irbesartan, losartan, olmesartan, and valsartan, are associated with a well-established synthesis-related nitrosamine formation pathway. The tetrazole ring is commonly synthesized using sodium nitrite (NaNO₂) in combination with polar aprotic solvents such as dimethylformamide (DMF). Under acidic conditions, residual dimethylamine originating from DMF can react with nitrous acid generated from NaNO₂, resulting in the formation of NDMA. Likewise, the presence of diethylamine impurities can lead to the generation of NDEA.
This pathway is primarily driven by process chemistry rather than formulation chemistry, making API-level testing and robust supplier controls the most important mitigation measures.
| Sartan | Primary Nitrosamine(s) | Formation Route | FDA AI Limit |
|---|---|---|---|
| Valsartan | NDMA, NDEA, NMBA | Tetrazole synthesis (DMF + NaNO₂) | NDMA: 96.0 ng/day |
| Losartan | NDEA | Tetrazole synthesis | NDEA: 26.5 ng/day |
| Irbesartan | NDMA | Tetrazole synthesis | NDMA: 96.0 ng/day |
| Candesartan | NDMA | Tetrazole synthesis | NDMA: 96.0 ng/day |
| Olmesartan | NDMA | Tetrazole synthesis | NDMA: 96.0 ng/day |
A critical distinction should be noted: sartans that do not contain a tetrazole ring, such as telmisartan, azilsartan, and eprosartan, are not exposed to this specific synthesis-related risk pathway. However, these products still require a comprehensive nitrosamine risk assessment to evaluate potential nitrosamine formation arising from excipients, packaging materials, and other manufacturing-related sources.
ACE Inhibitors: Secondary Amine Nitrosation Within the “Pril” Backbone
ACE inhibitors, including ramipril, lisinopril, enalapril, quinapril, and perindopril, contain secondary amine functionalities within their molecular structures that are inherently susceptible to N-nitrosation. Exposure to nitrite-containing excipients, degraded packaging components, or residual process contaminants can promote the formation of NDSRIs that are structurally related to the parent API rather than simple volatile nitrosamines such as NDMA.
A significant study published in 2024 demonstrated that N-nitroso-ramipril and N-nitroso-quinapril are non-genotoxic, as confirmed through both in vivo liver comet assays and Big Blue® mutation assays. Following these findings, the EMA revised its Article 5(3) guidance in May 2024 and established a new acceptable intake (AI) limit for N-nitroso lisinopril as a non-mutagenic impurity. This determination was based on a scientifically justified read-across approach using N-nitroso-quinapril data.
This regulatory development has important implications for CROs and pharmaceutical manufacturers. AI limit derivation for “pril” drug NDSRIs can no longer rely solely on Carcinogenic Potency Categorization Approach (CPCA) classification. Regulators increasingly accept and encourage scientifically supported read-across strategies based on published in vivo data when evaluating structurally related compounds.
From an analytical perspective, ACE inhibitor NDSRIs are relatively large and non-volatile molecules that often co-elute near the parent API. Accurate detection therefore requires advanced LC-MS/MS or LC-HRMS methods with exceptional chromatographic resolution. Peer-reviewed studies have demonstrated that phenyl-hexyl stationary phases can provide superior separation for challenging NDSRI/API pairs.
Learn how to leverage high-resolution mass spectrometry for complex structures: Explore HRMS for Nitrosamine Testing
Nitrosamine Testing for Beta-Blockers: A Distinct and Growing NDSRI Challenge
Nitrosamine testing for beta-blockers focuses on a separate category of NDSRIs that arise from secondary amine groups present within the ethanolamine or phenoxypropanolamine pharmacophore common to atenolol, bisoprolol, carvedilol, labetalol, metoprolol, and propranolol. These secondary amines are vulnerable to nitrosation when exposed to nitrite sources originating from excipients, degraded packaging materials, or environmental contaminants encountered during manufacturing.
Recent peer-reviewed research has described a validated unified LC-HRMS method capable of simultaneously analyzing six beta-blocker drug substances while achieving the following performance characteristics:
- Linearity: R² > 0.99 across calibration ranges for all target NDSRIs.
- Sensitivity: Limits of quantitation (LOQs) aligned with 10% of specification limits and limits of detection (LODs) approximately one-third of LOQ values.
- Confirmation: Ion-ratio confirmation for each NDSRI/API pair, providing robust regulatory-grade structural verification.
Although this methodology can be applied across multiple beta-blockers, each API possesses unique structural properties, including differences in secondary amine nucleophilicity, steric hindrance surrounding the nitrogen atom, and pKa values. These factors directly influence nitrosation kinetics and NDSRI formation potential. As a result, compound-specific CPCA assessments and API-specific AI limit determinations remain essential.
Understand how regulatory updates alter your risk portfolio: Read the Impact of ICH M7(R2) Updates on Nitrosamine Risk Assessment
Applying the Three-Step Compliance Framework to These Drug Classes
Both the FDA and EMA require manufacturers to follow a three-step investigative framework for nitrosamine control. However, the specific inputs and risk factors differ substantially across drug classes.
Step 1 — Risk Assessment
For Sartans:
- Assess synthetic routes involving NaNO₂, azide reagents, and DMF.
- Evaluate cross-contamination risks associated with shared manufacturing equipment.
- Review recovered solvent quality and impurity profiles.
For ACE Inhibitors:
- Identify pathways through which secondary amines may be exposed to nitrite-containing excipients and packaging materials.
- Assess gastric nitrosation potential using structure-activity relationship (SAR) models.
For Beta-Blockers:
- Evaluate nitrite content within excipients, particularly sodium starch glycolate and croscarmellose sodium.
- Assess the influence of water activity and storage temperature on nitrosation potential within finished dosage forms.
Step 2 — Confirmatory Analytical Testing
Validated, drug-class-specific analytical methods should be employed with sufficient sensitivity to detect impurities at levels equal to or below 10% of the applicable AI limit.
For Sartans:
- GC-MS/MS or headspace GC-MS for NDMA and NDEA.
- LC-MS/MS for NMBA and larger nitrosamine species.
For ACE Inhibitors and Beta-Blockers:
- LC-HRMS or LC-MS/MS methods utilizing NDSRI-specific reference standards.
Review the pros and cons of different gas chromatography sample introduction methods: Compare Direct Injection vs. Headspace Techniques for Nitrosamines
Discover specialized methodologies designed for small-molecule process impurities: Review GC-MS Method Development for Nitrosamine Testing
Step 3 — Mitigation and Control Strategy
Mitigation efforts may include:
- Process redesign and reformulation, such as solvent substitution during sartan synthesis.
- Enhanced excipient qualification and sourcing controls.
- Supplier qualification programs.
- Ongoing in-process monitoring to ensure continued compliance with established AI limits.
Regulatory Note: The FDA’s August 1, 2025 deadline for NDSRI confirmatory testing and submission of associated NDA/ANDA changes has passed. Manufacturers that have not completed testing and regulatory filings are now operating outside the recommended compliance timeline and should pursue expedited CRO-supported testing programs as soon as possible.
Achieve the low limits of quantitation required for modern compliance: Learn about Ultra-Low Limit of Quantitation (LOQ) in Nitrosamine Testing
CPCA Framework and AI Limits: Key Considerations for Manufacturers
The Carcinogenic Potency Categorization Approach (CPCA), endorsed by the FDA’s August 2023 NDSRI guidance, categorizes NDSRIs into five potency groups based on structural characteristics. These categories determine the applicable AI limit before compound-specific carcinogenicity or mutagenicity data become available.
| CPCA Category | Structural Basis | FDA AI Limit |
| 1 (Highest Potency) | α-methyl/unhindered NDSRI | 26.5 ng/day |
| 2 | Moderately hindered | 100 ng/day |
| 3 | α-hydroxyl or branched α | 400 ng/day |
| 4 | Sterically hindered α | 1,500 ng/day |
| 5 (TTC) | Predicted non-mutagenic | 1,500 ng/day |
For ACE inhibitor NDSRIs, steric hindrance around the α-carbon frequently places these impurities into higher CPCA categories. This often permits less restrictive AI limits and may support scientifically justified read-across approaches when supported by relevant in vivo data, reducing confirmatory testing requirements for structurally related compounds.
See how CPCA guidelines establish acceptable intake limits: Understand Nitrosamine AI Limit and CPCA
Compare standard limits across varying regulatory jurisdictions: Examine Nitrosamine AI Limits Comparison
Drug-Class-Specific CRO Services: Capabilities That Truly Matter
An effective CRO partner for nitrosamine testing across these cardiovascular drug classes must provide more than a standard validated multi-analyte panel. The scientific and regulatory requirements demand specialized expertise and infrastructure.
Custom NDSRI Reference Standard Synthesis
Many ACE inhibitor and beta-blocker NDSRIs are not commercially available. CROs must be capable of synthesizing these standards in-house, performing comprehensive structural characterization through NMR and HRMS, and verifying purity before method development and validation.
ICH Q2(R1)-Compliant Method Validation
Method validation should encompass:
- Accuracy
- Precision
- Specificity
- LOD and LOQ determination
- Linearity
- Analytical range
- Robustness
In addition, matrix-specific sample preparation strategies must be optimized for each formulation type.
CPCA-Aligned Toxicological Assessment
Qualified CROs should possess in-house expertise to:
- Classify NDSRIs according to CPCA criteria.
- Apply scientifically justified read-across methodologies.
- Develop AI limit justification packages using available toxicological data.
Regulatory Submission Documentation
Documentation should be prepared in formats suitable for:
- FDA NDA and ANDA submissions
- EMA variation dossiers
- Health Canada nitrosamine-related submissions
Generic laboratory reports are often insufficient for regulatory review.
Root Cause Analysis Support
When NDSRIs are detected above AI limits, CROs should provide comprehensive root cause investigations, process evaluation support, and assistance with Field Alert Report (FAR) preparation and submission.
ResolveMass Laboratories Inc. is among the few Canadian CROs capable of providing this full range of nitrosamine testing services entirely in-house. The organization operates validated LC-MS/MS and GC-MS/MS platforms within pharmaceutical-grade quality systems and employs PhD-level analytical chemists with extensive experience across sartan, ACE inhibitor, and beta-blocker product matrices. With more than a decade of specialized experience and hundreds of successful nitrosamine projects completed for both domestic and international clients, ResolveMass offers the scientific depth required to address complex drug-class-specific nitrosamine compliance challenges.
Discover how to structurally analyze and defend acceptable intake limits: Explore the Nitrosamine CPCA Approach for NDSRIs
Conclusion: Drug-Class Specificity in Nitrosamine Testing for Beta-Blockers, ACE Inhibitors, and Sartans Is Essential
Current scientific evidence and regulatory expectations leave little room for ambiguity: nitrosamine testing for beta-blockers, ACE inhibitors, and sartans requires distinct analytical and toxicological approaches. The mechanisms responsible for NDMA formation in tetrazole-containing sartans differ fundamentally from the excipient-driven NDSRI formation observed in beta-blocker formulations such as metoprolol tablets and from the secondary amine nitrosation pathways associated with ACE inhibitors such as ramipril.
Manufacturers that attempt to address these drug classes using a single analytical strategy risk either over-testing with inappropriate methodologies or under-testing in ways that leave significant impurities undetected and regulatory submissions incomplete.
With the FDA’s August 2025 compliance deadline now in effect, the opportunity for routine confirmatory testing and associated regulatory submissions has passed. For organizations that remain unfinished, engaging an experienced CRO with drug-class-specific expertise represents the most efficient path toward achieving compliance and reducing regulatory risk.
Ready to Build a Drug-Class-Specific Nitrosamine Testing Program for Your Cardiac Drug Portfolio?
📩 Contact ResolveMass Laboratories Inc. to speak with our nitrosamine testing specialists and request a comprehensive project scope review.
Frequently Asked Questions (FAQs)
Sartans and beta-blockers present different nitrosamine risks because their chemical structures and impurity formation pathways are not the same. Tetrazole-containing sartans are primarily associated with small-molecule nitrosamines such as NDMA and NDEA that originate during API synthesis. In contrast, beta-blockers are more likely to form nitrosamine drug substance-related impurities (NDSRIs) through nitrosation of secondary amine groups. As a result, each drug class requires distinct analytical methods, reference standards, and risk assessment strategies.
The FDA recommended that manufacturers complete NDSRI confirmatory testing and submit any necessary regulatory updates by August 1, 2025. Although this compliance milestone has now passed, manufacturers remain responsible for evaluating and controlling nitrosamine risks in marketed products. In certain situations where corrective actions could affect drug availability, companies may discuss interim acceptable intake (AI) approaches with the FDA. Regulatory expectations continue to emphasize timely risk mitigation and documentation.
ACE inhibitors that contain secondary amine functionalities are considered susceptible to nitrosamine formation and therefore require a documented nitrosamine risk assessment. Products such as ramipril, lisinopril, enalapril, quinapril, and perindopril fall within this category. Regulatory authorities expect manufacturers to evaluate the potential for NDSRI formation and conduct testing when appropriate. Available toxicological data for certain compounds may support read-across approaches that help streamline additional assessments.
LC-HRMS and LC-MS/MS are widely recognized as the preferred analytical platforms for beta-blocker NDSRI analysis. These techniques offer the sensitivity and selectivity required to detect trace-level nitrosamine impurities that are often non-volatile and structurally complex. Modern validated methods can simultaneously analyze multiple beta-blocker APIs while meeting regulatory expectations for accuracy, linearity, and detection capability. Their ability to provide structural confirmation makes them particularly valuable for compliance testing.
The Carcinogenic Potency Categorization Approach (CPCA) is a scientific framework used to estimate the carcinogenic potential of NDSRIs based on their molecular structure. The system classifies impurities into different potency categories by evaluating characteristics such as steric hindrance and α-carbon substitution patterns. Each category corresponds to a specific acceptable intake limit that guides regulatory decision-making. This approach helps manufacturers establish risk-based control strategies when compound-specific toxicology data are limited.
Although telmisartan, azilsartan, and eprosartan do not contain tetrazole rings and are not associated with the classic NDMA/NDEA synthesis pathway, they are not exempt from nitrosamine assessments. Regulatory agencies require manufacturers to evaluate all potential nitrosamine formation routes, including those related to excipients, packaging materials, and manufacturing conditions. A comprehensive risk assessment remains necessary to identify and control any possible impurity sources. Therefore, testing requirements are determined by risk rather than tetrazole content alone.
Many beta-blocker NDSRI reference standards are not commercially available and must be prepared through custom laboratory synthesis. Once synthesized, these materials require extensive characterization using techniques such as NMR spectroscopy and high-resolution mass spectrometry to confirm their identity and purity. Certified reference standards are essential for method development, validation, and regulatory submissions. Their availability is often a critical factor in successful NDSRI testing programs.
A properly validated LC-HRMS method can often support the analysis of several beta-blocker APIs within the same testing framework. However, the method must demonstrate acceptable specificity, sensitivity, linearity, and robustness for every API and associated NDSRI included in the scope. Chromatographic separation from each parent compound must also be clearly established. When validated correctly, this approach can improve efficiency for manufacturers managing multiple beta-blocker products.
Health Canada’s nitrosamine guidance is largely aligned with the regulatory principles adopted by both the FDA and EMA. The framework follows the same general process of risk assessment, confirmatory testing, and implementation of mitigation measures where necessary. In many cases, Health Canada also recognizes acceptable intake limits established by international regulators when Canadian-specific limits are unavailable. This harmonized approach helps facilitate consistent compliance expectations across multiple markets.
Reference:
- FDA. (2024, September). Control of Nitrosamine Impurities in Human Drugs – Revision 2. Guidance for Industry. U.S. Food and Drug Administration. https://www.federalregister.gov/documents/2024/09/05/2024-19883/control-of-nitrosamine-impurities-in-human-drugs-guidance-for-industry-availability
- FDA. (2023, August). Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs). Guidance for Industry. https://www.fda.gov/media/170794/download
- FDA CDER. (2025). CDER Nitrosamine Impurity Acceptable Intake Limits. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits
- EMA. (2024, May). Questions and Answers for Marketing Authorisation Holders/Applicants on the CHMP Opinion for the Article 5(3) Referral on Nitrosamine Impurities in Human Medicinal Products. EMA/409815/2020 Rev 20. https://www.ema.europa.eu
- EMA. (2019). Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group – Article 31 Referral Assessment Report. EMA/217823/2019. https://www.ema.europa.eu/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf
- ICH. (2023). M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. International Council for Harmonisation. https://www.ich.org
- Health Canada. (2023, October). Guidance on Nitrosamine Impurities in Medications. Government of Canada. https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance/guidance-nitrosamine%20impurities-medications.pdf
Get In Touch With Us
About The Author
